People: Tissue Therapies Ltd (TIS.AX)

TIS.AX on Australia Stock Exchange

0.31AUD
21 Oct 2014
Price Change (% chg)

$0.00 (+1.61%)
Prev Close
$0.31
Open
$0.31
Day's High
$0.32
Day's Low
$0.31
Volume
347,162
Avg. Vol
303,562
52-wk High
$0.47
52-wk Low
$0.22

Search Stocks

Summary

Name Age Since Current Position

Roger Clarke

2003 Non-Executive Chairman of the Board

Steven Mercer

2006 Chief Executive Officer, Managing Director, Executive Director

Drummond McKenzie

Chief Financial Officer, Company Secretary

Zee Upton

Chief Scientific Officer

Melvyn Bridges

64 2009 Non-Executive Director

Cherrell Hirst

2009 Non-Executive Director

Iain Ross

2012 Non-Executive Director

Biographies

Name Description

Roger Clarke

Mr. Roger Brian Clarke has been Non-Executive Chairman of the Board of Tissue Therapies Ltd since November 6, 2003. He has over 30 years of commercial experience, principally in the investment banking industry, with responsibilities in fund management, banking and corporate finance, and involvement in a number of initial public offerings, capital raisings and corporate transactions. He is Chairman of Board of Advice, RBS Morgans Limited; Chairman of NextDC Limited, Coalbank Limited and MTQ Insurance Ltd; Director of Trojan Equity Limited and Maverick Drilling and Exploration Limited. Mr. Clarke holds a Bachelor of Commerce degree and is a Chartered Accountant. He was a Director of PIPE Networks Limited. He is Chairman of the Audit and Risk Management Committee and Member of Remuneration Committee and Nomination Committee at the Company.

Steven Mercer

Dr. Steven J. Mercer has been Chief Executive Officer, Managing Director and Executive Director of Tissue Therapies Ltd since May 10, 2006. He holds Bachelor of Medical Science, Bachelor of Medicine, Bachelor of Surgery Fellow of the Australian Institute of Management Fellow of the Australian Institute of Company Directors Registered Medical Practitioner.He has significant medical and commercial experience as Managing Director of Mercy Tissue Engineering, a successful tissue engineering company. Significant international expertise prior to Tissue Therapies following a successful career with multinational companies, including six years with Smith & Nephew as General Manager, Smith & Nephew Surgical (Australia and New Zealand) and seven years with IBM Health Industry Centre in Australia and New York.

Drummond McKenzie

Mr. Drummond McKenzie is Chief Financial Officer and Company Secretary of Tissue Therapies Ltd. Mr. McKenzie holds Bachelor of Science (Economics) (Hons.) Fellow of the Institute of Chartered Accountants Fellow of the Institute of Chartered Secretaries.He has over 15 years experience in the financial management and administration of public companies.

Zee Upton

Ms. Zee Upton is Chief Scientific Officer of Tissue Therapies Ltd. Prof. Upton is VitroGro and oversees the Company's research activities as its Consulting Chief Scientific Officer. Prof. Upton is an biochemist and tissue engineer. She is Assistant Dean (Research) in the Faculty of Health, QUT and Leader of the Tissue Repair and Regeneration Program within the QUT Institute of Health and Biomedical Innovation.

Melvyn Bridges

Dr. Melvyn (Mel) John Bridges has been Non-Executive Director of Tissue Therapies Ltd since March 12, 2009. He holds a Bachelor of Science (Chemistry) and is Fellow of the Australian Institute of Company Directors. He has experience as a CEO and Company Director in healthcare, agricultural technology, drug development, pathology, diagnostics and medical devices. Related experience in retail. Has successfully raised in excess of $300 million investment capital in the healthcare/biotech sector and been directly involved in over $1 billion in M&A and related transactions. Director of ALS Limited (formerly Campbell Brothers Limited).

Cherrell Hirst

Dr. Cherrell Hirst has been Non-Executive Director of Tissue Therapies Ltd since June 30, 2009. She holds a Bachelor of Medicine, Bachelor of Surgery, Bachelor of Education Studies Honorary Doctorates from Queensland University of Technology, Griffith University and Southern Cross University Fellow of the Australian Institute of Company Directors Fellow of the Academy of Technological Sciences and Engineering.She has experience as Chairman of ImpediMed Limited and Director of Medibank Private Limited, Verva Pharmaceuticals Limited and the Gold Coast Hospital and Health Service Distinguished clinical career in the detection and treatment of breast cancer and extensive and respected achievements as Director and Chair of multiple commercial, government and not-for-profit organisations.

Iain Ross

Mr. Iain Gladstone Ross has been Non-Executive Director of Tissue Therapies Ltd since May 25, 2012. He holds a Bachelor of Science in Biochemistry from the University of London.He has experience as Chairman of Ark Therapeutics Plc (LSE), Biomer Technology Limited and Pharminox Limited, Director of Benitec BioPharma Limited, Novogen Limited, Anatara Lifesciences Limited and Yellow Cross Limited. Mr Ross is also a Vice Chairman and Trustee of Royal Holloway, London University.

Basic Compensation

Name Fiscal Year Total

Roger Clarke

87,400

Steven Mercer

424,390

Drummond McKenzie

214,345

Zee Upton

--

Melvyn Bridges

59,952

Cherrell Hirst

59,950

Iain Ross

59,750
As Of 29 Jun 2014

Options Compensation

Search Stocks